Price still isn’t right for Biogen’s blockbuster drug

Price still isn’t right for Biogen’s blockbuster drug
Michel Vounatsos, CEO, Biogen n Vounatsos was paid $13.6 million in pay, shares and other compensation in 2017

HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion

Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events.
  • Videos and podcasts from some of the industry's most respected journalists such as Michael Brennan, Susan Mitchell and Ian Guider.
  • Access to The Business Post's extensive archive​.

Related Articles

More from The Business Post